Replies to post #153116 on Biotech Values

[jq1234]

They expaned KRAS trial, it is going to use IHC - I believe they are going to use the same or similar testing for HCC, CRC trials. The reason they didn't use IHC in ph2 initially because it wasn't commercially available at that time, started to use it only after MetMab ph2 result was known.